On Tuesday, Zenas Biopharma (NASDAQ:ZBIO) stock received a new Overweight rating from Morgan Stanley, with a price target set at $40.00.
The firm's initiation of coverage on ZBIO is based on the potential of the company's drug obexelimab. Morgan Stanley sees the risk/reward for ZBIO's shares as favorable, particularly with significant updates expected in the coming years.
Zenas Biopharma's stock is currently valued modestly in relation to its peers in the inflammation and immunology (I&I) sector. This valuation comes ahead of what Morgan Stanley anticipates to be a period rich in developments for the company between 2024 and 2026.
The firm has identified the upcoming Phase II and Phase III trial updates for obexelimab in multiple sclerosis and IgG4-related disease (IgG4-RD) in 2025 as pivotal moments for ZBIO.
Obexelimab is being developed for several competitive indications. According to Morgan Stanley, the performance of ZBIO's stock may be influenced by data updates from competitors in the same indications, such as IgG4-RD, warm autoimmune hemolytic anemia (wAIHA), and systemic lupus erythematosus (SLE). Market volatility is a possibility as these competitor updates emerge.
Despite the potential for market fluctuations, Morgan Stanley maintains a positive outlook on the long-term trajectory of ZBIO's stock. The firm suggests that robust fundamental updates regarding obexelimab's development could lead to sustained upward movements in ZBIO's share price. This optimism is reflected in the Overweight rating and the $40 price target, indicating confidence in the stock's future performance.
In other recent news, Zenas Biopharma has seen positive coverage from both Guggenheim and Jefferies, with a focus on the potential of its lead drug, obexelimab.
Guggenheim initiated coverage with a Buy rating and a price target of $45.00, citing the drug's promising mechanism of action and potential for rapid recovery of B cells upon withdrawal. The firm also noted the drug's potential to generate approximately $1.8 billion in global risk-adjusted peak sales across two indications.
Similarly, Jefferies commenced coverage on Zenas Biopharma with a Buy rating and a price target of $35.00. The firm highlighted the company's focus on the immunology and inflammation sector, particularly noting obexelimab. Jefferies' projections estimate total peak adjusted revenues for Zenas Biopharma at approximately $1.6 billion.
Zenas Biopharma is currently advancing its Phase 3 study for obexelimab in IgG4-Related Disease (IgG4-RD), with results expected in late 2025. Additionally, Phase 2 trials for Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) are ongoing, with data anticipated in 2025 and early 2026, respectively. These recent developments underscore the potential for growth in Zenas Biopharma's future.
InvestingPro Insights
Recent data from InvestingPro adds context to Morgan Stanley's optimistic outlook on Zenas Biopharma (NASDAQ:ZBIO). The company's market capitalization stands at $781.24 million, reflecting investor interest in its potential. Notably, ZBIO has seen a significant 9.74% return over the last week, aligning with the positive sentiment expressed in the Morgan Stanley report.
However, investors should be aware of certain financial challenges. InvestingPro data shows that ZBIO is not profitable over the last twelve months, with a negative gross profit margin of -72.45%. This aligns with the company's development stage status, as it focuses on advancing obexelimab through clinical trials.
Two key InvestingPro Tips are particularly relevant to the article's context. First, ZBIO "holds more cash than debt on its balance sheet," which could provide financial flexibility for its ongoing clinical trials. Second, "liquid assets exceed short-term obligations," potentially offering stability as the company progresses through its critical 2024-2026 period.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips for ZBIO, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.